Streetbeat News

Analyst Ratings

ORIC

Baird analyst Colleen Kusy maintains an Outperform rating on ORIC Pharmaceuticals, but lowers the price target from $27 to $25.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 12:06 pm

AMRC

Exane BNP Paribas analyst Moses Sutton upgrades Ameresco (NYSE:AMRC) from Neutral to Outperform, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 12:04 pm

BLDP

HSBC analyst Samantha Hoh maintains a Buy rating on Ballard Power Systems (NASDAQ:BLDP) but lowers the price target from $4.5 to $4.1.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 12:04 pm

KBR

Recent analyst reviews on KBR (NYSE:KBR) show a generally bullish outlook, with 6 analysts offering insights over the past three months. The average 12-month price target for KBR is $69.33, marking a 4.73% increase from the previous target of $66.20. Analyst actions include both upgrades and a downgrade, with price targets ranging from $63.00 to $80.00. KBR, a global provider of engineering and construction services, reported a revenue growth of 7.59% and a net margin of 1.21% for the year 2023, indicating strong performance despite some challenges in debt management and return on equity.

Portfolio Pulse from Benzinga Insights

March 12, 2024 | 12:02 pm

TRMB

In the last three months, 6 analysts have updated their ratings on Trimble (NASDAQ:TRMB), with a shift towards a more bullish outlook. The average 12-month price target has increased by 15.6% to $63.00. Analysts from firms like Piper Sandler, Baird, and JP Morgan have raised their price targets, reflecting positive market conditions and Trimble's performance. Trimble has shown solid revenue growth of 8.86% as of December 31, 2023, with a net margin of 6.76% and ROE of 1.42%, indicating strong financial health despite a high debt-to-equity ratio of 0.71.

Portfolio Pulse from Benzinga Insights

March 12, 2024 | 12:02 pm

CVNA

Carvana (NYSE:CVNA) has been analyzed by 8 analysts in the last three months, showing a mix of sentiments from bullish to bearish. The average 12-month price target for CVNA has risen 60.39% to $64.38, with a range from $45.00 to $90.00. Analysts from firms like Jefferies, RBC Capital, Morgan Stanley, JMP Securities, and Wedbush have adjusted their ratings and price targets, reflecting a nuanced view of Carvana's market position. Despite the positive adjustments in price targets, Carvana faces financial challenges, including a -14.56% decline in revenue growth, below-average net margin, ROE, and ROA, and a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

March 12, 2024 | 12:01 pm

DXCM

Analysts have diverse views on DexCom (NASDAQ:DXCM), with recent evaluations showing a mix of bullish and somewhat bullish ratings. The average 12-month price target for DXCM has been raised to $153.25, indicating an 11.32% increase from the previous target. DexCom's financials show strong performance with a revenue growth rate of 26.9% and high net margin, although its debt management poses challenges.

Portfolio Pulse from Benzinga Insights

March 12, 2024 | 12:01 pm

LUV

Argus Research analyst John Staszak has upgraded Southwest Airlines (NYSE:LUV) from Hold to Buy and set a price target of $40.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 12:01 pm

NHI

National Health Investors (NYSE:NHI) received mixed reviews from 4 analysts, with a shift towards more bullish sentiments in the last 30 days. The average 12-month price target is now $65.75, marking a 17.41% increase from the previous target of $56.00. The company's financial performance shows strong revenue growth, net margin, ROE, and ROA, with a lower-than-average debt-to-equity ratio, indicating a solid financial position.

Portfolio Pulse from Benzinga Insights

March 12, 2024 | 12:00 pm

ACAD

Baird analyst Joel Beatty maintains an Outperform rating on ACADIA Pharmaceuticals (ACAD) but lowers the price target from $40 to $31.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 12:00 pm